# Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

> **NCT03595813** · NA · COMPLETED · sponsor: **Institut Paoli-Calmettes** · enrollment: 135 (actual)

## Conditions studied

- Lung Cancer Metastatic
- Locally Advanced Malignant Neoplasm
- Non Hodgkin Lymphoma
- Urologic Neoplasms

## Interventions

- **PROCEDURE:** Blood sample collection
- **PROCEDURE:** Biopsy collection

## Key facts

- **NCT ID:** NCT03595813
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-29
- **Primary completion:** 2020-07-17
- **Final completion:** 2025-06-25
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03595813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03595813, "Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03595813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*